IL31 and Alzheimer disease: Nemolizumab is a subcutaneously administered humanized monoclonal antibody against IL-31 receptor A. IL-31 blockage shows a direct effect against pruritus in AD patients (Nemoto et al., 2016; Oyama et al., 2018).